- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07949968
Hemodialysis Fistula-Related Ischemic Neuropathy in End-Stage Renal Failure: An Electrophysiological Study A Single Study in Assiut University Hospital (Hemodialysis)
Hemodialysis Fistula-Related Ischemic Neuropathy in End-Stage Renal Failure: An Electrophysiological Study A single study in Assiut university hospital
Study Overview
Status
Conditions
Detailed Description
End-stage renal failure (ESRF) represents a major global health burden, with hemodialysis being the most common renal replacement therapy. The creation of an arteriovenous fistula (AVF) Is considered the preferred vascular access for long-term hemodialysis due to its superior patency and lower complication rates compared to grafts and catheters (1-2) Despite its advantages, AVF creation may be associated with several complications, including ischemic steal syndrome and ischemic monomelic neuropathy (IMN). Ischemic neuropathy is a rare but potentially disabling complication resulting from acute or chronic ischemia of peripheral nerves following AVF creation. Patients may present with severe pain, sensory disturbances, weakness, and functional impairment of the affected limb (3-5) Early diagnosis remains challenging because symptoms may overlap with uremic neuropathy, diabetic neuropathy, and other peripheral nerve disorders commonly encountered in ESRF patients. Electrophysiological studies, including nerve conduction studies (NCS) and electromyography (EMG), provide objective assessment of nerve dysfunction and may facilitate early diagnosis and differentiation from other neuropathic conditions Limited data are available regarding the electrophysiological characteristics of AVF-related ischemic neuropathy, particularly in ESRF populations. Therefore, a comprehensive electrophysiological evaluation may contribute to improved recognition, management, and prevention of long-term disability
Hemodialysis fistula-related ischemic neuropathy is an under-recognized complication in patients with ESRF. Delayed diagnosis may lead to irreversible neurological deficits and impaired quality of life. The electrophysiological features and associated risk factors remain insufficiently characterized in many dialysis populations
This study aims to provide a detailed electrophysiological assessment of ischemic neuropathy associated with AVF creation in ESRF patients. The findings may facilitate early diagnosis, improve clinical outcomes, and contribute to developing screening and management strategies for high-risk patients
Aim of the Work:
To evaluate electrophysiological abnormalities associated with hemodialysis fistula-related ischemic neuropathy in patients with end-stage renal failure
- Primary Objective To assess peripheral nerve function using nerve conduction studies and electromyography in ESRF patients with AVF-related ischemic neuropathy
- Secondary Objectives To compare electrophysiological findings between ESRF patients with and without ischemic neuropathy To identify clinical and vascular factors associated with the development of ischemic neuropathy To determine the severity and distribution of nerve involvement To correlate electrophysiological findings with clinical manifestations and duration of AVF use
Patients and methods:
Type of the study: Analytical Cross-Sectional Case-Control Study Study Setting: The study will be conducted at Nephrology and Hemodialysis Unit at Assuit University hospital
Study duration: august 2026 - august 2027 Study populations: Patients diagnosed with end-stage renal failure undergoing maintenance hemodialysis through an arteriovenous fistula Group I (Cases) ESRF patients with clinical evidence of AVF-related ischemic neuropathy Group II (Controls)
- ESRF patients with functioning AVFs but without clinical evidence of ischemic neuropathy
- Presence of AVF
- Clinical manifestations suggestive of ischemic neuropathy after AVF creation
- Ability to provide informed consent ESRF patients on maintenance hemodialysis via AVF. No symptoms or signs of ischemic neuropathy Inclusion Criteria Age ≥18 years Diagnosed ESRF on regular hemodialysis Exclusion Criteria Pre-existing hereditary neuropathies Cervical radiculopathy Brachial plexopathy Motor neuron disease. Recent upper limb trauma. Peripheral nerve entrapment syndromes. Severe cognitive impairment. Refusal to participate
Methodology A. Clinical Assessment
All participants will undergo:
Detailed medical history, Dialysis history
AVF characteristics:
Site of fistula Duration since creation Side of fistula Previous vascular interventions
Neurological examination:
Motor assessment Sensory assessment Deep tendon reflexes Muscle strength grading using MRC scale B. Laboratory Investigations Complete blood count (CBC) Serum creatinine Blood urea nitrogen (BUN) Electrolytes HbA1c (for diabetic patients) Serum albumin Calcium and phosphorus levels C. Vascular Assessment Duplex Doppler ultrasonography of AVF Assessment of arterial flow and steal phenomenon D. Electrophysiological Assessment
Nerve Conduction Studies (NCS):
Electromyography (EMG)
Study Type
Enrollment (Estimated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
: Patients diagnosed with end-stage renal failure undergoing maintenance hemodialysis through an arteriovenous fistula Group I (Cases) ESRF patients with clinical evidence of AVF-related ischemic neuropathy Group II (Controls)
- ESRF patients with functioning AVFs but without clinical evidence of ischemic neuropathy
- Presence of AVF
- Clinical manifestations suggestive of ischemic neuropathy after AVF creation
- Ability to provide informed consent ESRF patients on maintenance hemodialysis via AVF. No symptoms or signs of ischemic neuropathy
Description
Inclusion Criteria:
- Age ≥18 years
- Diagnosed ESRF on regular hemodialysis
Exclusion Criteria:
- Pre-existing hereditary neuropathies
- Cervical radiculopathy
- Brachial plexopathy
- Motor neuron disease.
- Recent upper limb trauma.
- Peripheral nerve entrapment syndromes.
- Severe cognitive impairment.
- Refusal to participate
Study Plan
How is the study designed?
Design Details
- Observational Models: OTHER
- Time Perspectives: PROSPECTIVE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Motor Nerve Conduction Velocity
Time Frame: Up to 1 year post-AVF creation
|
Assessed by Nerve Conduction Studies on the upper limb with the arteriovenous fistula . Measured in meters per second. |
Up to 1 year post-AVF creation
|
|
Arteriovenous Fistula Blood Flow Volume
Time Frame: Up to 1 year post-AVF creation
|
Assessed by Duplex Doppler Ultrasound on the arteriovenous fistula. Measured in milliliters per minute. |
Up to 1 year post-AVF creation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensory Nerve Conduction Velocity
Time Frame: Up to 1 year post-AVF creation
|
Assessed by Nerve Conduction Studies on the upper limb with the arteriovenous fistula . Measured in meters per second |
Up to 1 year post-AVF creation
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Pathologic Processes
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Chronic Disease
- Disease Attributes
- Renal Insufficiency, Chronic
- Pathological Conditions, Signs and Symptoms
- Renal Insufficiency
- Kidney Failure, Chronic
Other Study ID Numbers
- SCT05147818
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.